Logo
x

Search

Subscribe Now

HUTCHMED

HUTCHMED Reports the NMPA’s NDA Acceptance of Tazemetostat for Treating Follicular Lymphoma

HUTCHMED Reports the NMPA’s NDA Acceptance of Tazemetostat for Treating Follicular Lymphoma

  • July 4, 2024
HUTCHMED Features the P-III (ESLIM-01) Study Data of Sovleplenib for Primary Immune Thrombocytopenia at EHA 2024

HUTCHMED Features the P-III (ESLIM-01) Study Data of Sovleplenib for Primary Immune Thrombocytopenia at EHA 2024

  • June 17, 2024
HUTCHMED Reports the P-III Trial Data and will Highlight Hematological Malignancy Programs at the EHA 2024

HUTCHMED Reports the P-III Trial Data and will Highlight Hematological Malignancy Programs at the EHA 2024

  • May 17, 2024
HUTCHMED Commences the P-II/III Study of Surufatinib Plus Camrelizumab for Pancreatic Ductal Adenocarcinoma

HUTCHMED Commences the P-II/III Study of Surufatinib Plus Camrelizumab for Pancreatic Ductal Adenocarcinoma

  • May 15, 2024
HUTCHMED Commences the P-III (RAPHAEL) Study of HMPL-306 for Treating Acute Myeloid Leukemia in China

HUTCHMED Commences the P-III (RAPHAEL) Study of HMPL-306 for Treating Acute Myeloid Leukemia in China

  • May 14, 2024
The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer

The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer

  • April 2, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.